Evidence map›Paper›PMID 40464766›Full record

ArticleHuman vaccines & immunotherapeutics2025

Seroepidemiological survey of the population 10 years after the implementation of the varicella vaccine 2-dose immunization strategy.

Quanjun Fang, Jilai Mao, Canya Fu, Xiaoying Gong, Canjie Zheng, Zhiying Yin

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Quanjun FangDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang, China.
Jilai MaoDepartment of Immunity, Jiangshan Center for Disease Control and Prevention, Zhejiang, China.
Canya FuSchool of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Xiaoying GongDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang, China.
Canjie ZhengDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang, China.
Zhiying YinDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang, China.ORCID 0000-0002-7678-5989

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the implementation of a two-dose varicella vaccine (VarV) immunization strategy for over a decade in Quzhou, China, outbreaks of varicella continue to be reported in school settings with high vaccination coverage. This cross-sectional study surveyed healthy individuals aged 3 to 20 years across six districts and counties in Quzhou, China. Serum samples were collected to detect varicella-zoster virus (VZV) IgG antibodies and to evaluate the effectiveness of the two-dose VarV immunization strategy. Among the 1,020 participants, the overall seropositivity rate for VZV IgG was 57.16%, with a median concentration (MC) of 136.46 mIU/mL. Multivariable logistic regression analysis revealed that VZV IgG seropositivity was associated with residence, age group, and VarV immunization history. Single-dose recipients exhibited an antibody peak at 4.34 years, followed by decline to a nadir at 7.95 years and subsequent rebound. In two-dose recipients, antibody levels declined rapidly within the first 1.82 years post-vaccination, followed by a gradual downward trend; nevertheless, levels consistently remained above the protective threshold of 100 mIU/mL. The necessity of booster immunization warrants further investigation.

Indexed as

Antibodies, ViralChickenpoxChickenpox VaccineAdolescentChildChild, PreschoolChinaCross-Sectional StudiesFemaleHerpesvirus 3, HumanHumansImmunization ScheduleImmunization, SecondaryImmunoglobulin GMaleSeroepidemiologic StudiesAntibodies, ViralChickenpox VaccineImmunoglobulin Gantibodyimmune responselive attenuated varicella vaccineVaricellavaricella-zoster virus

Identifiers

PMID40464766
PMCPMC12143688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.